RECENT NEWS
FierceBiotech  11 hrs ago  Comment 
The CEO of Belgium's Galapagos says that the biotech company is planning an important strategic shift, risking its money on solo drug development projects focused on rare diseases. Galapagos has made a name for itself partnering up on new drugs...
China Securities  11 hrs ago  Comment 
Jan. 26, 2010 (Business Wire) -- China Kangtai Cactus Biotech Inc. (OTCBB: CKGT), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based products in China, announced today that it has received a RMB 14.30...
PR Newswire  Jan 26  Comment 
PLYMOUTH, Minn., Jan. 26 /PRNewswire-FirstCall/ -- The Mosaic Company (NYSE: MOS) announced today that it will participate in the Goldman Sachs Fourteenth Annual Agricultural Biotech Forum taking place on Wednesday, February 10, 2010. The forum will
FierceBiotech  Jan 26  Comment 
Welcome to our look back at the new drug approvals of 2009. Last year the FDA gave the green light to an impressive 26 new therapies, slightly beating the 2008 total of 25. Of those, seven were newly-approved biologics, leading analysts to wonder...
Clean Energy Sector  Jan 26  Comment 
In the UK, researchers publishing in the quarterly magazine of the Biotechnology and Biological Sciences Research Council say that they have discovered a method to increase the quantity of [fermentable] glucomannan in plant stems “with no...
TheStreet.com  Jan 26  Comment 
Middleby produces commercial food-service equipment. It will never be a hot stock, which makes it a compelling investment.
BusinessWeek  Jan 25  Comment 
Amgen Inc., the world’s largest biotechnology company, said fourth-quarter profit rose 1 percent. The earnings missed analysts’ estimates.
FierceBiotech  Jan 25  Comment 
Over the weekend, the biotech field was the subject of a rare Hollywood closeup, with the development of a new therapy for Pompe disease a central theme in the newly released 'Extraordinary Measures.' Alas, despite featuring such heavyweight...
MarketWatch  Jan 25  Comment 
Drug stocks are sluggish in early trading as shares of Poniard Pharmaceuticals sink after it reports mixed mid-stage clinical data for its chemotherapy drug candidate picoplatin.
FierceBiotech  Jan 25  Comment 
Intercept Pharmaceuticals' majority shareholder, the Italian biotech Genextra, is pumping a $25 million Series B into its coffers. "This financing is recognition of the success we have had advancing our lead compounds INT-747 and INT-777," said...



Thank you for your suggestion
RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS

Biotechnology is the use of molecular biology and genetic engineering techniques to develop treatments for human diseases. Many leading companies from the industry originated in the late 70's from university research laboratories. In the 1980s after attracting venture investors and after listed in the US stock exchange,have then developed into a growing industry that uses research innovations to develop new agricultural products, biomedical tools, and human therapies such as monoclonal antibody for cancer. In 2006, 92% of employees in the biotechnology industry worked in companies that specialized in developing new drugs or medical devices and equipment, while 8% were employed in companies that specialized in agricultural products. [1] The large cap company in the group is Amgen, Genentech, Biogen-Idec, Genzyme. iShares Nasdaq Biotechnology (IBB) offers a low risk/reward investment vehicle for long term investors




Industry Information

Major Biotechnology Companies

ISTA Pharmaceuticals (ISTA)

Biotechnology Industry Trends & Forces

High Pipeline Risk for New Drugs

Dependence on Health Insurance/Medicare Coverage

Dependence on Governmental Regulations

High Volatility and Instability at Start-up

Litigation Risk

Market Share

References

  1. State Bioscience Initiatives 2008 Report, published by the Biotechnology Industry Organization

Companies in the Biotechnology Industry (202)

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki